Drug Profile
Loxoprofen sodium/methocarbamol
Alternative Names: IP-TN; Loxoprofen/methocarbamolLatest Information Update: 18 Feb 2022
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Class Analgesics; Muscle relaxants; Nonsteroidal anti-inflammatories
- Mechanism of Action Cyclooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 18 Feb 2022 Discontinued - Phase-III for Pain (In adolescents, In the elderly, In adults) in Japan (PO)
- 01 Oct 2016 Boehringer Ingelheim completes a phase III trial in Pain in Japan (NCT02831569)
- 27 Jul 2016 Chemical structure information added